CLYM

Climb Bio, Inc.

Insider Trades

NameValueActionPriceCurrent Price
Thomas Stephen BasilDirector
$114k16.3k shares
SellFeb 26, 2026
$7.01
--
Thomas Stephen BasilDirector
$236k33.7k shares
SellFeb 25, 2026
$7.00
--
Thomas Stephen BasilDirector
$58k10k shares
SellFeb 13, 2026
$5.81
--
Thomas Stephen BasilDirector
$471k90k shares
SellFeb 12, 2026
$5.23
--
Ra Capital Management, L.p.Director, 10 Percent Owner:
$25k7.1k shares
BuyJan 5, 2026
$3.50
--
Ra Capital Management, L.p.Director, 10 Percent Owner:
$290k101.5k shares
BuyDec 12, 2025
$2.86
--

News

globenewswire.comClimb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026globenewswire.comJun 11globenewswire.comClimb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Developmentglobenewswire.comJun 5globenewswire.comClimb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026globenewswire.comMay 26marketbeat.comClimb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnectmarketbeat.comMay 21globenewswire.comClimb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congressglobenewswire.comMay 14